Cargo Therapeutics is a biotechnology company that specializes in developing precision therapeutics for cancer treatment. Their proprietary technology platform enables the targeted delivery of small molecules and biologics to cancer cells, while minimizing off-target effects on healthy cells. The company's lead product candidate, CT-100, is a novel therapeutic that selectively targets cancer cells expressing the protein EphA2, which is overexpressed in a variety of solid tumors. Cargo Therapeutics aims to improve patient outcomes and reduce the toxicity of cancer treatments with their precision therapeutics.
View Enterprise Value for Cargo Therapeutics.